Paul Benn

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure

Martin Fisher, Paul Benn, B.G. Evans et al. · International Journal of STD & AIDS · 2006 · 153 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +16

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond et al. · The Lancet HIV · 2021 · 135 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

Susan Swindells, Thomas A. Lutz, Lelanie Van Zyl et al. · AIDS · 2021 · 97 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011)

Paul Benn, Martin Fisher, Ranjababu Kulasegaram · International Journal of STD & AIDS · 2011 · 90 citations · Full text

Public Health, Infectious Disease Control, Pharmacoeconomics +17